Initiating and Intensifying Insulin Therapy in Type 2 Diabetes Mellitus

American Journal of Medicine

Volumn 121, Issue 6 SUPPL., 2008, Pages

  Tibaldi, Joseph ^a  

^a FLUSHING HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Basal Insulin; Insulin; Insulin Initiation; Insulin Intensification; Premix Insulin; Type 2 Diabetes Mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; EXENDIN 4; HUMAN INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; MEGLITINIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

ALGORITHM; ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; EDEMA; HUMAN; HYPOGLYCEMIA; INJECTION SITE PAIN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PATIENT ATTITUDE; PATIENT CARE; PATIENT EDUCATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; SIDE EFFECT; WEIGHT GAIN;

DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN; INSULIN, LONG-ACTING;

EID: 44249109983     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2008.03.023     Document Type: Article

References (53)

1. American College of Endocrinology Consensus Statement on Guidelines for Glycemic Control. http://www.aace.com/meetings/consensus/dcc/pdf/dccwhitepaper.pdf Accessed April 18, 2008
2. American College of Endocrinology Consensus Statement on Guidelines for Glycemic Control, 2001. Endocr Pract. 8 suppl 1 (2002) 5-11. http://www.aace.com/meetings/consensus/dcc/pdf/dccwhitepaper.pdf Available at: http://www.aace.com/meetings/consensus/dcc/pdf/dccwhitepaper.pdf. Accessed March 14, 2007
3. American Diabetes Association. Standards of medical care in diabetes-2007. Diabetes Care 30 suppl1 (2007) S4-S41
4. ACE/AACE Diabetes Road Map Task Force, 2007. Road maps to achieve glycemic control in type 2 diabetes mellitus [ACE/AACE Diabetes Recommendations Implementation Conference; AACE Website]. Endocr Pract. 13 (2007) 260-268. http://www.aace.com/meetings/consensus/odimplementation/roadmap.pdf Available at: http://www.aace.com/meetings/consensus/odimplementation/roadmap.pdf. Accessed April 17, 2007
5. Peyrot M., Rubin R.R., Lauritzen T., et al., International DAWN Advisory Panel. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 28 (2005) 2673-2679
6. Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord. 26 suppl 3 (2002) S18-S24
7. UK Prospective Diabetes Study Group 16. Overview of 6 years' therapy of type 2 diabetes: a progressive disease. Diabetesz 44 (1995) 1249-1258
8. Kahn S.E., Haffner S.M., Heise M.A., et al., ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [published correction appears in N Engl J Med. 2007;356:1387-1388]. N Engl J Med. 355 (2006) 2427-2443
9. White N.H., Cleary P.A., Dahms W., Goldstein D., Malone J., Tamborlane W.V., and Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT). J Pediatr. 139 (2001) 804-812
10. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 15 (2002) 2563-2569 287
11. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 290 (2003) 2159-2167
12. Stratton I.M., Adler A.I., Neil H.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS35): prospective observational study. BMJ 321 (2000) 405-412
13. Ceglia L., Lau J., and Pittas A.G. Meta-analysis: efficacy and safety of inhaled insulin therapy in adults with diabetes mellitus. Ann Intern Med. 145 (2006) 665-675
14. Riddle M.C., Rosenstock J., Gerich J., and Insulin Glargine 4002 Study Investigators. The Treat-to-Target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26 (2003) 3080-3086
15. Philis-Tsimikas A., Charpentier G., Clauson P., Ravn G.M., Roberts V.L., and Thorsteinsson B. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther. 28 (2006) 1569-1581
16. Hermansen K., Davies M., Derezinski T., Martinez Ravn G., Clauson P., and Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naïve people with type 2 diabetes. Diabetes Care 29 (2006) 1269-1274
17. Graff M.R., and McClanahan M.A. Assessment by patients with diabetes mellitus of two insulin pen delivery systems versus a vial and syringe. Clin Ther. 20 (1998) 486-496
18. Summers K.H., Szeinbach S.L., and Lenox S.M. Preference for insulin delivery systems among current insulin users and nonusers. Clin Ther. 26 (2004) 1498-1505
19. Rex J., Jensen K.H., and Lawton S.A. A review of 20 years' experience with the NovoPen family of insulin injection devices. Clin Drug Investig. 26 (2006) 367-401
20. Kvapil M., Swatko A., Hilberg C., and Shestakova M. Biphasic insulin aspart 30 plus metformin: an effective combination in type 2 diabetes. Diabetes Obes Metab 8 (2006) 39-48
21. Macfarlane D.P., and Fisher M. Thiazolidinediones in patients with diabetes mellitus and heart failure: implications of emerging data. Am J Cardiovasc Drugs 6 (2006) 297-304
22. Standl E., Maxeiner S., Raptis S., and HOE901/4009 Study Group. Once-daily insulin glargine administration in the morning compared to bedtime in combination with morning glimepiride in patients with type 2 diabetes: an assessment of treatment flexibility. Horm Metab Res. 38 (2006) 172-177
23. Eliaschewitz F.G., Calvo C., Valbuena H., et al., HOE 901/4013 LA Study Group. Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride. Arch Med Res. 37 (2006) 495-501
24. Garber A.J., Wahlen J., Wahl T., et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 Study). Diabetes Obes Metab. 8 (2006) 58-66
25. Raskin P., Allen E., Hollander P., et al., INITIATE study group. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 28 (2005) 260-265
26. Malone J.K., Kerr L.F., Campaigne B.N., et al., Lispro Mixture-Glargine Study Group. Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. [published correction appears in Clin Ther. 2005;27:1112]. Clin Ther. 26 (2004) 2034-2044
27. Sun P., Wang R., and Jacober S.J. Therapeutic effectiveness of two insulin regimens for insulin naive patients with type 2 diabetes mellitus: once-daily basal insulin or twice-daily premixed insulin?. Diabetes 55 suppl 1 (2006) Abstract 427-P
28. Malone J.K., Bai S., Campaigne B.N., Reviriego J., and Augendre-Ferrante B. Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with Type 2 diabetes. Diabet Med. 22 (2005) 374-381
29. Rolla A. The pathophysiological basis for intensive insulin replacement. Int J Obes Relat Metab Disord. 28 suppl 2 (2004) S3-S7
30. Del Prato S., and Marchetti P. Beta- and alpha-cell dysfunction in type 2 diabetes. Horm Metab Res. 36 (2004) 775-781
31. Middelbeek R.J., and Horton E.S. The role of glucose as an independent cardiovascular risk factor. Curr Diab Rep. 7 (2007) 43-49
32. Monnier L., Colette C., Monnier L., and Colette C. Contributions of fasting and postprandial glucose to hemoglobin A1c. Endocr Pract. 12 suppl 1 (2006) 42-46
33. Gough S.C. A review of human and analogue insulin trials. Diabetes Res Clin Pract. 77 (2007) 1-15
34. Bolli G.B., and Owens D.R. Insulin glargine. Lancet 356 (2000) 443-445
35. Havelund S., Plum A., Ribel U., et al. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm Res. 21 (2004) 1498-1504
36. Klein O., Lynge J., Endahl L., Damholt B., Nosek L., and Heise T. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes Metab. 9 (2007) 290-299
37. Fritsche A., Schweitzer M.A., Haring H.U., and 4001 Study Group. Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med. 138 (2003) 952-959
38. Massi Benedetti M., Humburg E., Dressler A., and Ziemen M. A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Horm Metab Res. 35 (2003) 189-196
39. 1c on glycemic control in patients with type 2 diabetes: the Glycemic Optimization with Algorithms and Labs at Point of Care (GOAL A1C) trial. Diabetes Care 29 (2006) 1-8
40. Yki-Jarvinen H., Kauppinen-Makelin R., et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 49 (2006) 442-451
41. Rašlová K., Tamer S.C., Clauson P., and Karl D. Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes, and this advantage increases with baseline body mass index. Clin Drug Investig. 27 (2007) 279-285
42. Meneghini L.F., Rosenberg K.H., Koenen C., Merilainen M.J., and Luddeke H.J. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naïve or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study. Diabetes Obes Metab. 9 (2007) 418-427
43. Davies M., Storms F., Shutler S., et al., ATLANTUS Study Group. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care 28 (2005) 1282-1288
44. Kilo C., Mezitis N., Jain R., Mersey J., McGill J., and Raskin P. Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin. J Diabetes Complications 17 (2003) 307-313
45. Kabadi U.M., and Kabadi M. Comparative efficacy of glimepiride and/or metformin with insulin in type 2 diabetes. Diabetes Res Clin Pract. 72 (2006) 265-270
46. ® Mix 70/30 once or twice daily is more efficacious than optimizing oral treatment in patients with type 2 diabetes. [abstract]. Diabetes 54 suppl 1 (2005) A510
47. 1c <7% by adding biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment. Diabetologia 49 suppl 1 (2006) 487 [abstract 803]
48. Lingvay I., Kaloyanova P.F., Adams-Huet B., Salinas K., and Raskin P. Insulin as initial therapy in type 2 diabetes: effective, safe, and well accepted. J Investig Med. 55 (2007) 62-68
49. Tibaldi J. Biphasic insulin aspart 70/30 three times a day in older patients with Type 2 diabetes not achieving optimal glycemic control on a twice-daily regimen: A retrospective case series analysis from clinical practice. Adv Ther 24 (2007) 1348-1356
50. Luzio S., Dunseath G., Peter R., Pauvaday V., and Owens D.R. Comparison of the pharmacokinetics and pharmacodynamics of biphasic insulin aspart and insulin glargine in people with type 2 diabetes. Diabetologia 49 (2006) 1163-1168
51. 1c in patients with type 2 diabetes. Diabetes 55 suppl 1 (2006) Abstract 514-P
52. Bergenstal R.M., Johnson M.L., Powers M.A., Wynne A.G., Vlajnic A., and Hollander P.A. Using a simple algorithm (ALG) to adjust mealtime glulisine (GLU) based on preprandial glucose patterns is a safe and effective alternative to carbohydrate counting (Carb Count). Diabetes 55 suppl 1 (2006) Abstract 441-P
53. Liebl A., Prager R., Binz K., Kaiser M., Gallwitz B., and PREFER Study Group. The PREFER Study: both biphasic insulin Aspart 30 (BIAsp 30) twice-daily and basal-bolus using insulin detemir (IDet) and insulin aspart (IAsp) enabled patients with type 2 diabetes to achieve A1c target <7.0%. Diabetologia 49 suppl 1 (2006) 610 [abstract 998]